Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.91 +1.62%

+$0.05 today

Market cap
$191.64M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.26M

Average 0.32M

Returns on capital

Galectin Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

24.4%

avg -259.6%

ROIC

-174.3%

avg -390.1%

ROA

-157.9%

avg -153.7%

Analysis

ROE is currently the strongest return metric at 24.4% versus its period average of -259.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joel Lewis

President & CEOUSD 992.02K5691.00K0.14%

Khurram Jamil

Chief Medical OfficerUSD 921.58K500<0.01%

Jack W. Callicutt

Chief Financial Officer, Treasurer & Corporate SecretaryUSD 676.02K5965.00K0.10%

Jim Wilkins

Head of CMC & Pharmaceutical Development————

Robert Tritt

General Counsel————

Beth Knowles

Executive Assistant & Officer Manager————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 14, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$22,935.00

Sells

37

$4.82M

Net Transaction Value

−$4.80M

Net selling

Most Active

Shlevin Harold H.

14 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 14, 26

Jamil Khurram

Direct

Sell$83.3K
Jun 29, 26

Shlevin Harold H.

Direct

Sell$112.2K
Jun 29, 26

Jamil Khurram

Direct

Sell$239.2K
Jun 26, 26

Shlevin Harold H.

Direct

Sell$38.7K
Jun 26, 26

Jamil Khurram

Direct

Sell$12.7K
Jun 23, 26

Jamil Khurram

Direct

Sell$23.7K
May 26, 26

Jamil Khurram

Direct

Sell$1.8K
Feb 6, 26

ELDRED KARY

Direct

Buy$810
Jan 6, 26

CALLICUTT JACK W

Direct

Sell$74.7K
Jan 6, 26

Jamil Khurram

Direct

Sell$78.2K

1–10 of 40

Summary

Insiders reported 3 buys worth $22,935.00 and 37 sells worth $4.82M over the last 12 months. That adds up to net selling of $4.80M. Shlevin Harold H. was the most active insider with 14 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Galectin Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GALT's management, answered from reported figures.

Who manages GALT?

Galectin Therapeutics Inc. (GALT) lists 6 active executives. The top listed executive is Khurram Jamil, Chief Medical Officer.

Are GALT insiders buying or selling?

Recent insider activity shows net buying of $102.85M.